The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 11, 2006, Pages 1649-1653

  Mourad, Walid A ^a   Tulabah, Asma ^a   Al Sayed, Adher ^a   Raja, Madras ^a   Khafaga, Yasser ^a   El Gamal, Hazem ^a   Al Shabanah, Mohamed ^a   Al Meshari, Khaled ^a   Al Shaibani, Khaled ^a   Ezzat, Adnan ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; PREDNISONE; TSUKUBAENOLIDE;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CHILD; CLINICAL ARTICLE; CLONAL VARIATION; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; HISTIOCYTIC SARCOMA; HUMAN; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; REVIEW; SARCOMA; WORLD HEALTH ORGANIZATION CLASSIFICATION;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; GENES, T-CELL RECEPTOR; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PHENOTYPE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 33750579668     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of posttransplantation lymphoproliferative disorders. J Nephrol. 1997;10:136-145.
2. Swinnen LJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am. 1997;11:963-973,
3. Nalesnik MA. Clinicopathologic characteristics of posttransplant lymphoproliferative disorders. Recent Results Cancer Res. 2002;159:9-18.
4. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145-155.
5. Herzig KA, Juffs HG, Norris D, et al. A single centre experience of post-renal transplant lymphopraliferative disorder. Transpl Int. 2003;16:529-536.
6. Shroff R, Rees L. The posttransplant lymphoproliferative disorder: a literature review. Pediatr Nephrol. 2004;19:365-368.
7. Soler MJ, Puig JM, Mir M, et al. Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant patients. Transplant Proc. 2003;35: 1709-1713.
8. Swinnen LJ. Organ transplant-related lymphoma. Curr Treat Options Oncol. 2001;2:301-308.
9. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol. 1997;14:2-7.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-269. World Health Organization Classification of Tumours; vol. 3.
11. Durandy A. Anti-B and anticytokine therapy for the treatment of posttransplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis. 2001;3:104-107.
12. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation. 1969;8:209-212.
13. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200-217.
14. Knowles DM. The molecular genetics of posttransplant lymphoproliferative disorders. Springer Semin Immunopathol. 1998;20:357-373.
15. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society of Hematopathology workshop. Semin Diagn Pathol. 1997;14:8-14.
16. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood. 1995;85:552-565.
17. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplant lymphoproliferative disorders are clinically relevant. Cancer. 1998;82:1978-1987.
18. Lundell R, Elenitoba-Johnson KSJ, Lim M. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol. 2004;28:967-973.
19. Wang LC, Lu MY, Yu J, Jou ST, Chiang IP, Lin DT. T-cell lymphoproliferative disorder following bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 2000;26:893-897.
20. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with posttransplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003;9:3945S-3953S.
21. Davis CL. Interferon and cytotoxic chemotherapy for the treatment of posttransplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:108-118.